For HCPs

Dosing Attruby

Convenient
1-month supply1

1 monthly carton includes 4 weekly blister packs for 712 mg (two 356-mg tablets) twice per day

No concomitant medications or supplements required per label

Person reviewing Attruby® packaging

How to explain dosing to patients1:

The recommended dosage is two 356-mg tablets of Attruby (acoramidis) taken orally, twice a day, with or without food. Tablets should be swallowed whole. Do not cut, crush, or chew. Instruct your patients to always take Attruby (acoramidis) as prescribed, building it into their daily routine.

9 out of 10 patients with ATTR-CM already take medication multiple times per day.2*

  • *Based on descriptive analyses of chronic oral medication use in patients from ATTRibute-CM (N=632) and real-world data of patients with ATTR-CM (N=4725) from Optum Clinformatics Data Mart.2

ATTR-CM=transthyretin amyloid cardiomyopathy

References:

  1. Attruby. Prescribing Information. BridgeBio Pharma, Inc. 2024.
  2.  Dasgupta N, Poulsen SH, Emdin M, et al. Contemporary oral medication use and frequency in patients with transthyretin amyloid cardiomyopathy. Am J Cardiovasc Drugs. 2025;25(6):829-839. doi:10.1007/s40256-025-00752-x.

Important Safety Information and Indication

Important Safety Information

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Indication

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.

You’re about to leave AttrubyHCP.com and visit an external site. BridgeBio is not responsible for the content or privacy practices of the site you’re about to redirect to.

BridgeBio is committed to protecting and respecting your privacy. All information collected will be handled in accordance with our Privacy Policy. By clicking "Submit," you agree to share your contact information and certain health information with BridgeBio, BridgeBio affiliates, and companies working with BridgeBio or BridgeBio affiliates (collectively, "BridgeBio"). You agree that BridgeBio may contact you by mobile or online digital media, mail, email, fax, telephone call, and text messages (including autodialed and prerecorded calls and messages) for marketing purposes, including targeted online marketing, or to otherwise provide you with information about BridgeBio's products, treatment, or other offers. You can unsubscribe from these communications at any time by clicking "Unsubscribe" in the communications you receive.

More information on DDIs1

Avoid concomitant use of Attruby (acoramidis) with UGT inducers and strong CYP3A inducers, as these can potentially decrease Attruby exposure.

Consider more frequent monitoring for evidence of increased exposure to CYP2C9 substrates when Attruby (acoramidis) is coadministered with sensitive CYP2C9 substrates.

CYP=cytochrome P450; DDI=drug-drug interaction; UGT=uridine diphosphate glucuronosyltransferase.

Established Safety Profile4

Patients With 1 or More Events Attruby
n=421, % (n)		 Placebo
n=211, % (n)
Any TEAEs 98.1% (413) 97.6% (206)
Any treatment-emergent SAEs 54.6% (230) 64.9% (137)
Any treatment-related TEAEs 11.9% (50) 5.2% (11)
Severe TEAEs 37.3% (157) 45.5% (96)

SAE=serious adverse event; TEAE=treatment-emergent adverse event.